Curran Terrie's Form 4 filing
Arcutis Biotherapeutics, Inc.ARQT · filed Aug 28, 2026
- Accession no.
- 0001628280-26-059444
- Filed
- Aug 28, 2026, 5:40 PM ET
- Trade date
- Aug 27, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $956.1K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Curran TerrieCIK 0001690298 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Common Stock | MOption exerciseAcquired | +11,148 | $7.51 | +$83,721.48 | 34,674 | Direct | |
| Aug 27, 2026 | Common Stock | SSaleDisposed | −11,148 | $25.03F2 | −$279,027.75 | 23,526 | Direct | |
| Aug 27, 2026 | Common Stock | MOption exerciseAcquired | +27,052 | $8.63 | +$233,458.76 | 50,578 | Direct | |
| Aug 27, 2026 | Common Stock | SSaleDisposed | −27,052 | $25.03F2 | −$677,095.33 | 23,526 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Common Stock | MOption exerciseDisposed | −11,148 | $0.00 | $0 | 0 | Direct | |
| Aug 27, 2026 | Common Stock | MOption exerciseDisposed | −27,052 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.